Explain this page
Arphra AIPlain-English read on Carpenter Technology Corporation’s valuation06-08today
- Carpenter Technology (CRS) is a Top-Ranked Momentum Stock: Should You Buy?1d
- Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partner4d
- Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partner4d
- Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-197d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$228.98
-60.96% vs spot
Recommendation
Sell
18 of 19 methods
Method spread
0bull18bear
±5% threshold
Analyst PT consensus: $465.80 (-20.58%)
Candlestick · 1Y
Open in chart workstation →CRS
586.47+131.15%H 593.18L 228.00MA50 460.34MA200 356.73Avg vol 870K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.91% | +3.05% | +38.97% | +61.83% | +79.27% | +86.28% | +131.15% | +1025.66% | +1346.65% | +1581.88% | +12042.24% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$591.99
Bid
$572.00
2 sh
Ask
$620.42
1 sh
Spread
$48.420
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 Mar 2026 | $811.5M | $139.6M | $2.77 |
| Q2 Dec 2025 | $728M | $105.3M | $2.09 |
| Q1 Sep 2025 | $733.7M | $122.5M | $2.43 |
| Q4 Jun 2025 | $755.6M | $111.7M | $2.21 |
| Q3 Mar 2025 | $727M | $95.4M | $1.88 |
| Q2 Dec 2024 | $676.9M | $84.1M | $1.66 |
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Carpenter Technology (CRS) is a Top-Ranked Momentum Stock: Should You Buy?zacks.com·Jun 18, 2026
- Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partnerglobenewswire.com·Jun 15, 2026
- Supporting the Mission: Catholic Relief Services Chooses Adstra as a Fundraising Partnerglobenewswire.com·Jun 15, 2026
- Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19zacks.com·Jun 12, 2026
- Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?zacks.com·Jun 10, 2026
- Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19businesswire.com·Jun 10, 2026
- Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19businesswire.com·Jun 10, 2026
- Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Termzacks.com·Jun 08, 2026
Peers
No peer list available for CRS.
Total assets
$3.49B
Total debt
$738.3M
Cash & equiv
$315.5M
Operating CF
$440.4M
Free cash flow
$286.1M
Buybacks
-$101.9M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $2.88B | $521.8M | $376M | $7.42 | +13.07% |
| FY 2024 | $2.76B | $323.1M | $186.5M | $3.70 | +6.76% |
| FY 2023 | $2.55B | $133.1M | $56.4M | $1.14 | +2.21% |
| FY 2022 | $1.84B | -$24.9M | -$49.1M | $-1.01 | -2.67% |
| FY 2021 | $1.48B | -$248.6M | -$229.6M | $-4.75 | -15.56% |